Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline High Grade Gliomas

Currently On Hold

The objective of this expanded access program is to provide ONC201 to eligible patients with previously-treated glioma that exhibits the H3 K27M mutation and/or that is located in the midline region of the brain.

Participate in a Clinical Trial

Learn More